Physician profile
Erica Ramey
NPI 1992121297
$5,053.78
in general payments reported to CMS, 2019-2025
15 companies · $660 in 2025
The $660 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $480 · 2022: $64.81 · 2023: $3,255 · 2024: $594 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,906 · Food and Beverage: $1,575 · Education: $27.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,906.25 |
| Food and Beverage | $1,575.01 |
| Education | $27.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,299.11 | 2022-2025 | Austedo Xr, Austedo Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $398.60 | 2023-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $380.00 | 2021 | |
| Abbvie INC. | $329.50 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.94 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $114.58 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $102.43 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $69.56 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.99 | 2021 | |
| Supernus Pharmaceuticals, INC. | $38.24 | 2024-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $27.70 | 2024 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $27.53 | 2023 | Trintellix |
| Lundbeck LLC | $18.02 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $15.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Ramey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.